2.27
+0.01(+0.44%)
Currency In USD
| Previous Close | 2.26 |
| Open | 2.23 |
| Day High | 2.3 |
| Day Low | 2.2 |
| 52-Week High | 6.6 |
| 52-Week Low | 1 |
| Volume | 118,514 |
| Average Volume | 1.43M |
| Market Cap | 23.63M |
| PE | -0.57 |
| EPS | -3.99 |
| Moving Average 50 Days | 2.24 |
| Moving Average 200 Days | 2.29 |
| Change | 0.01 |
If you invested $1000 in SAB Biotherapeutics, Inc. (SABS) since IPO date, it would be worth $22.36 as of September 07, 2025 at a share price of $2.27. Whereas If you bought $1000 worth of SAB Biotherapeutics, Inc. (SABS) shares 3 years ago, it would be worth $333.33 as of September 07, 2025 at a share price of $2.27.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes
GlobeNewswire Inc.
Sep 03, 2025 8:05 PM GMT
MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a multi-specific human anti-thymocyt
SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates
GlobeNewswire Inc.
Aug 07, 2025 11:30 AM GMT
Recently raised $175 million in oversubscribed private placement which included strategic investor Sanofi and top-tier biotech investors Strong cash position with completed financing extending operational runway until the middle of 2028 Achieved ali
SAB BIO Announces Oversubscribed $175 Million Private Placement
GlobeNewswire Inc.
Jul 21, 2025 11:30 AM GMT
Participation from strategic investor Sanofi, along with new investors RA Capital Management, Commodore Capital, Vivo Capital, Blackstone Multi-Asset Investing, Spruce Street Capital, Forge Life Science Partners and Woodline Partners LP, and existing